Transcriptomic profiling of uterine serous carcinoma models treated with the CDK12 inhibitor CTX-439
This study investigates transcriptomic changes in uterine serous carcinoma (USC) following treatment with the CDK12 inhibitor CTX-439. RNA-seq was performed on xenograft tumors derived from USC cell lines (ARK1, ARK2) and patient-derived xenograft (PDX) models (USC1, USC2) in mice treated with either CTX-439 or vehicle control. Differential expression analysis was conducted to identify CTX-439-responsive genes and pathways.